Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1α in non-small cell lung cancer A549 cells

Lung cancer is one of the most frequently occurring and fatal cancer types worldwide. Cisplatin is widely used for chemotherapy of non-small cell lung cancer (NSCLC). However, the use of cisplatin has been met with the challenge of chemoresistance as a result of hypoxia, which is common in adult sol...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Qiang, Lan, Fei, Yan, Xu, Xiao, Zhu, Wu, Yuelei, Zhang, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019907/
https://www.ncbi.nlm.nih.gov/pubmed/29971135
http://dx.doi.org/10.3892/ol.2018.8767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019907/
https://www.ncbi.nlm.nih.gov/pubmed/29971135
http://dx.doi.org/10.3892/ol.2018.8767

Ejemplares similares